Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 5:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 155 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Migraine Headache Clear all
Not listed Phase 1Phase 2 Interventional

Treatment of Chronic Migraine Headaches.

NCT03220113
View directory record Official record
Conditions
Chronic Migraine Without Aura, Intractable, Migraine With Typical Aura, Migraine Disorders
Interventions
Dexamethasone, Lidocaine, Thiamine cohort
Combination Product
Lead sponsor
Corona Doctors Medical Clinics, Inc.
Other
Eligibility
10 Years to 90 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Corona, California
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 4 Interventional Results available

Novel Insight Into Migraine Pathophysiolgy and Galcanezumab Mechanisms of Action

NCT04271202
View directory record Official record
Conditions
Chronic Migraine
Interventions
Emgality 120 MG in 1 ML Prefilled Syringe
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brookline, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Erenumab in Adults With Medication Overuse Headache

NCT03971071
View directory record Official record
Conditions
Migraine Headache
Interventions
Erenumab 70 mg, Erenumab 140 mg, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
32
States / cities
Cerritos, California • Colton, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 1 Interventional

Occipital Nerve Stimulation for the Treatment of Chronic Migraine Headache.

NCT00200109
View directory record Official record
Conditions
Chronic Migraine Headache
Interventions
Occipital Nerve Stimulation
Device
Lead sponsor
MedtronicNeuro
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
7
States / cities
Scottsdale, Arizona • Oceanside, California • Denver, Colorado + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2011 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

NCT04530110
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
32
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 4 Interventional Results available

Onabotulinumtoxin Type A Reconstitution With Preserved Versus Preservative-free Saline in Chronic Migraine.

NCT03698409
View directory record Official record
Conditions
Chronic Migraine, Headache
Interventions
Preserved saline in reconstitution of Botox
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years to 79 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Sep 25, 2026, 5:53 AM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

Clinical Applications of High-Frequency Oscillations

NCT00600717
View directory record Official record
Conditions
Epilepsy, Migraine, Headache, Pain, Autism, Cerebral Palsy, Brain Development, Traumatic Brain Injury, ADHD - Attention Deficit Disorder With Hyperactivity, Mental Health
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 69 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 25, 2026, 5:53 AM EDT
Not yet recruiting Not applicable Interventional

Dietary Intervention for Migraine Relief

NCT07360405
View directory record Official record
Conditions
Migraine
Interventions
Dietary training
Behavioral
Lead sponsor
American University
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine

NCT03108469
View directory record Official record
Conditions
Chronic Migraine
Interventions
IONIS-PKKRx (ISIS 546254), Placebo
Drug · Other
Lead sponsor
Smith, Timothy R., M.D.
Individual
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
City of Saint Peters, Missouri • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 11, 2020 · Synced Sep 25, 2026, 5:53 AM EDT
Withdrawn Phase 2 Interventional

Transnasal Sphenopalatine Ganglia Block for Management of Chronic Migraines in Pediatric Patients

NCT04466826
View directory record Official record
Conditions
Migraine in Children, Pain, Neuropathic
Interventions
Headache Journal, Sphenopalatine Block, Tx360
Other · Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
8 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Sep 25, 2026, 5:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

fMRI of the Brainstem in Migraine Sufferers and Controls. Does Iron Deposition Correlate With Progression of Disease?

NCT00868556
View directory record Official record
Conditions
Episodic Migraine, Chronic Daily Migraine
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 4, 2010 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

NINDS CRC Chronic Migraine Treatment Trial

NCT00772031
View directory record Official record
Conditions
Chronic Migraine
Interventions
propranolol LA, topiramate, placebo
Drug
Lead sponsor
Anne Lindblad
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
39
States / cities
Phoenix, Arizona • Tuscon, Arizona • Chico, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2012 · Synced Sep 25, 2026, 5:53 AM EDT
Suspended Not applicable Interventional

Vibratory Stimulation for the Treatment of Chronic Pain

NCT04069572
View directory record Official record
Conditions
Chronic Pain, Pelvic Pain, Functional Abdominal Pain Syndrome, Low Back Pain, Migraine
Interventions
Vibrotactile Stimulation, Sham Stimulation
Device
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 2 Interventional Results available

Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments

NCT03844412
View directory record Official record
Conditions
Vestibulodynia, Temporomandibular Disorder, Fibromyalgia Syndrome, Irritable Bowel Syndrome, Migraines, Tension Headache, Endometriosis, Interstitial Cystitis, Back Pain, Chronic Fatigue Syndrome
Interventions
5% lidocaine/5 mg/ml 0.02% estradiol compound cream, Nortriptyline, Placebo cream, Placebo pill
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
209 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Los Angeles, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

Occipital Blocks for Acute Migraine

NCT03526874
View directory record Official record
Conditions
Chronic Migraine, Headache, Episodic Migraine
Interventions
Lidocaine 4% Topical Application Cream [LMX 4], Lidocaine Hydrochloride 2 mg/mL Injectable Solution, Normal Saline
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
7 Years to 21 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 3 Interventional

Evaluating the Safety and Tolerability of OraVescent Fentanyl for Opioid Tolerant Patients With Noncancer Related Breakthrough Pain

NCT00228605
View directory record Official record
Conditions
Low Back Pain, Migraine, Diabetic Neuropathies, Osteoarthritis
Interventions
OraVescent Fentanyl
Drug
Lead sponsor
Cephalon
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
38
States / cities
Calera, Alabama • Hoover, Alabama • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 4 Interventional Results available

Duration of Benefit for OnabotulinumtoxinA in Treatment of Chronic Migraine

NCT02037425
View directory record Official record
Conditions
Chronic Migraine
Interventions
onabotulinumtoxinA
Drug
Lead sponsor
Cady, Roger, M.D.
Individual
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Phase 3 Interventional Results available

An Open Label Trial of ALD403 (Eptinezumab) in Chronic Migraine

NCT02985398
View directory record Official record
Conditions
Migraine Disorder
Interventions
ALD403 (Eptinezumab)
Biological
Lead sponsor
Alder Biopharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
20
States / cities
San Diego, California • Santa Monica, California • Colorado Springs, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Sep 25, 2026, 5:53 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Aspirin Resistance in Women With Migraine

NCT01257893
View directory record Official record
Conditions
Episodic Migraine, Chronic Migraine
Interventions
Aspirin (acetylsalicylic acid), Placebo
Drug
Lead sponsor
Swedish Medical Center
Other
Eligibility
18 Years to 50 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Sep 25, 2026, 5:53 AM EDT
Active, not recruiting Not applicable Interventional

A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM

NCT06167655
View directory record Official record
Conditions
Headache Migraine Chronic
Interventions
Neurostimulator
Device
Lead sponsor
ShiraTronics
Industry
Eligibility
22 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 25, 2026, 5:53 AM EDT
Completed Not applicable Interventional

CBT Depression Intervention for Co-Occurring Chronic Headache

NCT02870725
View directory record Official record
Conditions
Depression, Headaches Chronic, Migraine Disorders
Interventions
CBT Individual Psychotherapy
Behavioral
Lead sponsor
University of Georgia
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Athens, Michigan • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 25, 2026, 5:53 AM EDT
Recruiting Not applicable Interventional

Topical Intranasal Anesthetic Block for Reducing the Pain of Botulinum Toxin Injections for Chronic Migraine

NCT07571889
View directory record Official record
Conditions
Pain From onabotulinumtoxinA Injections
Interventions
onabotulinumtoxinA prophylaxis with Lidocaine, OnabotulinumtoxinA prophylaxis with Saline
Procedure
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
East Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Sep 25, 2026, 5:53 AM EDT
Recruiting Phase 3 Interventional

A Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine

NCT07729462
View directory record Official record
Conditions
Preventive Treatment of Migraine
Interventions
Rimegepant, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Canoga Park, California • Boca Raton, Florida • Papillion, Nebraska + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 25, 2026, 5:53 AM EDT
Recruiting Phase 3 Interventional

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant, Placebo for Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 17 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
32
States / cities
Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 29 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 25, 2026, 5:53 AM EDT